At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
E2027drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology
In Brief
A Phase 2 clinical trial evaluating E2027 for Lewy Body Disease and Parkinson Disease. Completed, enrolled 34 participants across 14 sites in 2 countries.
Detailed Summary
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLewy Body Disease, Parkinson Disease
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartFeb 2021
Primary CompletionDec 2021
Study CompletionJan 2022
TodayJul 2026
First PostedFeb 21, 2021
Enrollment StartFeb 25, 2021
Primary CompletionDec 8, 2021
Study CompletionJan 27, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.4 years ago
Interventions
E2027drug
Oral hypromellose capsules.